- Price
- $64.01
- Day
- +2.81%
- Mkt Cap
- $6.19B
- 52W Range
- $32.78 – $72.66
- Volume
- 628.2K
- Beta
- 0.61
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eleven new non-officer employees consisting of an aggregate of 32,758 share options and 19,013 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Read full article
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026.
Read full article
Bank of New York Mellon Corp grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) by 2.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 396,138 shares of the biopharmaceutical company's stock after acquiring an
Read full article
Castleark Management LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 64,563 shares of the biopharmaceutical company's stock, valued at approximately $3,754,000. Castleark Management
Read full article
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is progressing toward a Q3 2026 NDA filing. The company has a cash runway through 2029, supporting ongoing Phase 3 trials in MDD, bipolar depression, and pain, and is building a commercial infrastructure.
Read full article